参考文献/References:
[1] Zhao HL,Sui Y,Guan J, et al.Fat redistribution and adipocyte transformation in uninephrectomized rats[J].Kidney Int,2008,74(4):467-477.
[2] Koppe L,Pillon NJ,Vella RE, et al.p-Cresyl sulfate promotes insulin resistance associated with CKD[J].J Am Soc Nephrol,2013,24(1):88-99.
[3] Vaziri ND,Yuan J,Ni Z, et al.Lipoprotein lipase deficiency in chronic kidney disease is accompanied by down-regulation of endothelial GPIHBP1 expression[J].Clin Exp Nephrol,2012,16(2):238-243.
[4] Jin K,Norris K,Vaziri ND.Dysregulation of hepatic fatty acid metabolism in chronic kidney disease[J].Nephrol Dial Transplant,2013,28(2):313-320.
[5] Axelsson J,Astr?m G,Sj?lin E, et al.Uraemic sera stimulate lipolysis in human adipocytes: role of perilipin[J].Nephrol Dial Transplant,2011,26(8):2485-2491.
[6] Pelletier CC,Koppe L,Croze ML, et al.White adipose tissue overproduces the lipid-mobilizing factor Zinc α2-glycoprotein in chronic kidney disease[J].Kidney Int,2013,83(5):878-886.
[7] Roubicek T,Bartlova M,Krajickova J, et al.Increased production of proinflammatory cytokines in adipose tissue of patients with end-stage renal disease[J].Nutrition,2009,25(7/8):762-768.
[8] Zhao HL,Sui Y,He L, et al.Lipid partitioning after uninephrectomy[J].Acta Diabetol,2011,48(4):317-328.
[9] Kalbacher E,Koppe L,Zarrouki B, et al.Human uremic plasma and not urea induces exuberant secretion of leptin in 3T3-L1 adipocytes[J].J Ren Nutr,2011,21(1):72-75.
[10] Li J,Guan M,Li C, et al.The dipeptidyl peptidase-4 inhibitor sitagliptin protects against dyslipidemia-related kidney injury in apolipoprotein E knockout mice[J].Int J Mol Sci,2014,15(7):11416-11434.
[11] Declèves AE,Zolkipli Z,Satriano J, et al.Regulation of lipid accumulation by AMP-activated kinase [corrected] in high fat diet-induced kidney injury[J].Kidney Int,2014,85(3):611-623.
[12] Chavez JA,Summers SA.A ceramide-centric view of insulin resistance[J].Cell Metab,2012,15(5):585-594.
[13] Li Z,Woollard JR,Wang S, et al.Increased glomerular filtration rate in early metabolic syndrome is associated with renal adiposity and microvascular proliferation[J].Am J Physiol Renal Physiol,2011,301(5):F1078-F1087.
[14] Tanaka Y,Kume S,Araki SI, et al.Fenofibrate, a PPARα agonist, has renoprotective effects in mice by enhancing renal lipolysis[J].Kidney Int,2011,79(8):871-882.
[15] Jauregui A,Mintz DH,Mundel P, et al.Role of altered insulin signaling pathways in the pathogenesis of podocyte malfunction and microalbuminuria[J].Curr Opin Nephrol Hypertens,2009,18(6):539-545.
[16] Welsh GI,Hale LJ,Eremina V, et al.Insulin signaling to the glomerular podocyte is critical for normal kidney function[J].Cell Metab,2010,12(4):329-340.
[17] Lennon R,Pons D,Sabin MA, et al.Saturated fatty acids induce insulin resistance in human podocytes: implications for diabetic nephropathy[J].Nephrol Dial Transplant,2009,24(11):3288-3296.
[18] Holland WL,Miller RA,Wang ZV, et al.Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin[J].Nat Med,2011,17(1):55-63.
[19] Siew ED,Ikizler TA.Insulin resistance and protein energy metabolism in patients with advanced chronic kidney disease[J].Semin Dial,2010,23(4):378-382.
[20] Samuel VT,Liu ZX,Wang A, et al.Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease[J].J Clin Invest,2007,117(3):739-745.
[21] Sun X,Pan H,Tan H, et al.High free fatty acids level related with cardiac dysfunction in obese rats[J].Diabetes Res Clin Pract,2012,95(2):251-259.
[22] Ouwens DM,Sell H,Greulich S, et al.The role of epicardial and perivascular adipose tissue in the pathophysiology of cardiovascular disease[J].J Cell Mol Med,2010,14(9):2223-2234.
[23] Kerr JD,Holden RM,Morton AR, et al.Associations of epicardial fat with coronary calcification, insulin resistance, inflammation, and fibroblast growth factor-23 in stage 3-5 chronic kidney disease[J].BMC Nephrol,2013,14:26.
相似文献/References:
[1]张睿,刘帅辉,于珮.痛风合并慢性肾脏疾病的药物治疗[J].国际内分泌代谢杂志,2016,36(02):82.[doi:10.3760/cma.j.issn.1673-4157.2016.02.003]
Zhang Rui,Liu Shuaihui,Yu Pei..Drug therapy of gout combined with chronic kidney disease[J].International Journal of Endocrinology and Metabolism,2016,36(06):82.[doi:10.3760/cma.j.issn.1673-4157.2016.02.003]
[2]杜娟,夏维波.成纤维细胞生长因子-23的代谢调控及与疾病的关系[J].国际内分泌代谢杂志,2017,37(02):123.[doi:10.3760/cma.j.issn.1673-4157.2017.02.014]
Du Juan,Xia Weibo..The metabolic regulation of fibroblast growth factor-23 and its relation with diseases[J].International Journal of Endocrinology and Metabolism,2017,37(06):123.[doi:10.3760/cma.j.issn.1673-4157.2017.02.014]
[3]《恩格列净/二甲双胍复方制剂临床应用专家指导意见》编写组.恩格列净/二甲双胍复方制剂临床应用专家指导意见[J].国际内分泌代谢杂志,2022,42(05):451.[doi:10.3760/cma.j.cn121383-20220530-05068]
Expert Group for Guidance of EMPA/MET FDC.Expert opinion on empagliflozin/metformin fixed-dose combination for treatment of type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2022,42(06):451.[doi:10.3760/cma.j.cn121383-20220530-05068]